1-114713908-T-G
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Moderate
The NM_002524.5(NRAS):c.182A>C(p.Gln61Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q61L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_002524.5 missense
Scores
Clinical Significance
Conservation
Publications
- Noonan syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- Noonan syndrome 6Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia
- cardiofaciocutaneous syndromeInheritance: AD Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, ClinGen
- Costello syndromeInheritance: AD Classification: LIMITED Submitted by: ClinGen
- Noonan syndrome with multiple lentiginesInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| NRAS | NM_002524.5 | c.182A>C | p.Gln61Pro | missense_variant | Exon 3 of 7 | ENST00000369535.5 | NP_002515.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| NRAS | ENST00000369535.5 | c.182A>C | p.Gln61Pro | missense_variant | Exon 3 of 7 | 1 | NM_002524.5 | ENSP00000358548.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Noonan syndrome 6 Pathogenic:1
not provided Pathogenic:1
The Q61P variant in the NRAS gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The Q61P variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The Q61P variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position in codon 61 of the guanosine triphosphate-binding site that is conserved across species. The guanosine trisphophate-binding site is crucial for normal inactivation, and variants located at this site lead to constitutive activation of NRAS (Kinsler et al., 2013). Two missense variants in the same residue (Q61R, Q61K) have been reported previously as somatic alterations in association with congenital melanocytic nevi and thyroid follicular carcinomas and adenomas, supporting the functional importance of this region of the protein (Nikiforova et al., 2003; Dessars et al., 2009; Kinsler et al., 2013; Lim et al., 2014). We interpret Q61P as a pathogenic variant.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at